NCT05974150Recruiting
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 26 Jul 2023
- Start date
- 19 Jul 2023
- Primary completion date
- 5 Nov 2026
- Lead sponsor
- Carevive Systems, Inc.
- NCT number
- NCT05974150
What you commit to
- Study type: Observational
- Planned participants: 25
- From 19 Jul 2023 to the primary completion date, 5 Nov 2026
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Any patient who cannot understand written or spoken English.
- Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
- Any patient on a treatment clinical trial.
- Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).
Who the study is looking for
- All participants must be 18 years of age or older.
- Subjects may be any stage and anywhere in the treatment continuum.
- Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
- Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
- All participants must be able to understand English.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Mercy Hospital Coordinator of this site? Confirm its status | Canton | United States | Recruiting |
| Univeristy of North Carolina at Chapel Hill Coordinator of this site? Confirm its status | Chapel Hill | United States | Completed |
| University Hospitals Seidman Cancer Center Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
| Duke Coordinator of this site? Confirm its status | Durham | United States | Completed |
| Northshore University Health System Coordinator of this site? Confirm its status | Evanston | United States | Recruiting |
| Tri-County Hematology & Oncology Associates, Inc. Coordinator of this site? Confirm its status | Massillon | United States | Recruiting |
| Yale Cancer Center Coordinator of this site? Confirm its status | New Haven | United States | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.